Frequent copresence of methylated DNA and fragmented nucleosomal DNA in plasma of lymphoma patients

Clinica Chimica Acta

Volumn 335, Issue 1-2, 2003, Pages 89-94

  Deligezer, Ugur ^a   Yaman, Fulya ^a   Erten, Nilgün ^b   Dalay, Nejat ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

^b ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Fragmentation; Lymphoma; Methylation; p16; Plasma DNA

Indexed keywords

BIOCHEMICAL MARKER; CELL NUCLEUS DNA; DNA FRAGMENT; PROTEIN P16; RESTRICTION ENDONUCLEASE;

ANALYTICAL PARAMETERS; ARTICLE; CANCER PATIENT; CANCER STAGING; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE MARKER; DNA DETERMINATION; DNA METHYLATION; EARLY DIAGNOSIS; EXON; GEL ELECTROPHORESIS; HUMAN; HUMAN CELL; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; NUCLEOSOME; PLASMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION MAPPING; TUMOR SUPPRESSOR GENE;

EID: 0242317395     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-8981(03)00279-1     Document Type: Article

References (25)

1. Leon S.A., Shapiro B., Sklaroff D.M., Yaros M.J. Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res. 37:1977;646-650.
2. Stroun M., Lyautey J., Lederrey C., Olson-Sand A., Anker P. About the possible origin and mechanism of circulating DNA apoptosis and active DNA release. Clin. Chim. Acta. 313:2001;139-142.
3. Anker P. Quantitative aspects of plasma/serum DNA in cancer patients. Ann. N. Y. Acad. Sci. 906:2000;5-7.
4. Shaw J.A., Smith B.M., Walsh T.et al. Microsatellite alterations in plasma DNA of primary breast cancer patients. Clin. Cancer Res. 6:2000;1119-1124.
5. Yamada T., Nakamori S., Ohzato H.et al. Detection of K-ras gene mutations in plasma DNA of patients with pancreatic adenocarcinoma: correlation with clinicopathological features. Clin. Cancer Res. 4:1998;1527-1532.
6. Wong I.H., Lo Y.M., Johnson P.J. Epigenetic tumor markers in plasma and serum: biology and applications to molecular diagnosis and disease monitoring. Ann. N. Y. Acad. Sci. 945:2001;36-50.
7. Herman J.G., Merlo A., Mao L.I.et al. Inactivation of the CDKN2/p16 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res. 55:1995;4525-4530.
8. Esteller M., Corn P.G., Baylin S.B., Herman J.G. A gene hypermethylation profile of human cancer. Cancer Res. 61:2001;3225-3229.
9. Okajima E., Fukuda T., Okita S., Tsutsumi M., Hirao Y., Konishi Y. Infrequent somatic alterations of p16/MTS1 in human primary superficial bladder cancers. Cancer Lett. 103:1996;227-231.
10. Shimizu T., Sekiya T. Loss of heterozygosity at 9p21 loci and mutations of the MTS1 and MTS2 genes in human lung cancers. Int. J. Cancer. 63:1995;616-620.
11. Garcia J.F., Villuendas R., Algara P.et al. Loss of p16 protein expression associated with methylation of the p16INK4A gene is a frequent finding in Hodgkin's disease. Lab. Invest. 79:1999;1453-1459.
12. Garcia M.J., Martinez-Delgado B., Cebrian A., Martinez A., Benitez J., Rivas C. Different incidence and pattern of p15INK4b and p16INK4a promoter region hypermethylation in Hodgkin's and CD30-positive non-Hodgkin's lymphomas. Am. J. Pathol. 161:2002;1007-1013.
13. Baur A., Shaw P., Burri N., Deleacrehaz F., Bosman F.T., Chaubert P. Frequent methylation silencing p15 and p16 in B-cell and T-cell lymphomas. Blood. 94:1999;1773-1781.
14. Child F.J., Scarisbrick J.J., Calonje E., Orchard G., Russell-Jones R., Whittaker S.J. Inactivation of tumor suppressor genes p15(INK4b) and p16(INK4a) in primary cutaneous B cell lymphoma. J. Invest. Dermatol. 118:2002;941-948.
15. Nakamura M., Sakaki T., Hashimoto H.et al. Frequent alterations of the p14(ARF) and p16(INK4a) genes in primary central nervous system lymphomas. Cancer Res. 61:2001;6335-6339.
16. Kraus A., Schuermann M. Molecular detection of gene mutations and methylation abnormalities: applications in solid tumor diagnosis. Expert Rev. Mol. Diagn. 2:2002;97-108.
17. Kamb A., Gruis N.E., Weaver-Feldhaus J.et al. A cell cycle regulator potentially involved in genesis of many tumor types. Science. 264:1994;436-440.
18. Wong I.H., Johnson P.J., Lai P.B., Lau W.Y., Lo Y.M. Tumor-derived epigenetic changes in the plasma and serum of liver cancer patients. Implications for cancer detection and monitoring. Ann. N. Y. Acad. Sci. 906:2000;102-105.
19. Nomoto S., Nakao A., Kasai Y.et al. Peritoneal washing cytology combined with immunocytochemical staining and detecting mutant K-ras in pancreatic cancer: comparison of the sensitivity and availability of various methods. Pancreas. 14:1997;126-132.
20. Esteller M., Sanches-Cespedes M., Rosell R., Sidransky D., Baylin S.B. Detection of aberrant promoter hypermethylation of tumor supressor genes in serum from non-small cell lung cancer patients. Cancer Res. 59:1999;67-70.
21. Sorenson G.D. Detection of mutated KRAS2 sequences as tumor markers in plasma/serum of patients with gastrointestinal cancer. Clin. Cancer Res. 6:2000;2129-2137.
22. Benharroch D., Levy A., Prinslo I.et al. Apoptotic index as a prognostic factor in Hodgkin's disease. Leuk. Lymphoma. 33:1999;351-359.
23. Horning S.J., Galili N., Cleary M., Sklar J. Detection of non-Hodgkin's lymphoma in the peripheral blood by analysis of antigen receptor rearrangements results of a prospective study. Blood. 75:1990;1139-1145.
24. Jahr S., Hentze H., Englisch S.et al. DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res. 61:2001;1659-1665.
25. An Q., Liu Y., Gao Y.et al. Detection of p16 hypermethylation in circulating plasma DNA of non-small cell lung cancer patients. Cancer Lett. 188:2002;109-114.